Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, Morgan Stanley Analyst Says

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective boosted by equities research analysts at Morgan Stanley from $767.00 to $768.00 in a report issued on Friday,Benzinga reports. The brokerage currently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s target price points to a potential upside of 3.60% from the stock’s previous close.

Several other brokerages have also issued reports on REGN. Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, December 8th. Cantor Fitzgerald boosted their price objective on Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the company an “overweight” rating in a research note on Wednesday, October 29th. Royal Bank Of Canada upped their price objective on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the company a “sector perform” rating in a report on Wednesday, October 29th. UBS Group increased their target price on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. Finally, Wells Fargo & Company boosted their price target on shares of Regeneron Pharmaceuticals from $700.00 to $745.00 and gave the company an “equal weight” rating in a research report on Wednesday. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $779.45.

Regeneron Pharmaceuticals Stock Down 0.7%

REGN opened at $741.29 on Friday. Regeneron Pharmaceuticals has a twelve month low of $476.49 and a twelve month high of $790.98. The company’s 50-day moving average price is $664.44 and its two-hundred day moving average price is $592.75. The stock has a market cap of $77.91 billion, a price-to-earnings ratio of 17.75, a PEG ratio of 2.12 and a beta of 0.37. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The company had revenue of $3.75 billion for the quarter, compared to analysts’ expectations of $3.57 billion. During the same quarter in the previous year, the firm posted $12.46 EPS. Regeneron Pharmaceuticals’s revenue was up .9% on a year-over-year basis. As a group, equities analysts expect that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Christine A. Poon sold 6,500 shares of the company’s stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the sale, the director owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. This represents a 73.43% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Jason Pitofsky sold 431 shares of the stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the sale, the vice president owned 4,233 shares in the company, valued at $2,757,503.19. This represents a 9.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 7.02% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Allworth Financial LP grew its holdings in shares of Regeneron Pharmaceuticals by 50.5% during the third quarter. Allworth Financial LP now owns 1,496 shares of the biopharmaceutical company’s stock worth $841,000 after purchasing an additional 502 shares in the last quarter. IFP Advisors Inc lifted its position in Regeneron Pharmaceuticals by 14.2% during the third quarter. IFP Advisors Inc now owns 1,405 shares of the biopharmaceutical company’s stock valued at $790,000 after purchasing an additional 175 shares during the last quarter. Swiss Life Asset Management Ltd grew its stake in Regeneron Pharmaceuticals by 112.0% in the 3rd quarter. Swiss Life Asset Management Ltd now owns 23,658 shares of the biopharmaceutical company’s stock worth $13,302,000 after buying an additional 12,500 shares in the last quarter. Cambria Investment Management L.P. increased its holdings in shares of Regeneron Pharmaceuticals by 21.8% in the 3rd quarter. Cambria Investment Management L.P. now owns 3,090 shares of the biopharmaceutical company’s stock worth $1,737,000 after buying an additional 554 shares during the last quarter. Finally, Pointe Capital Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 37.0% in the 3rd quarter. Pointe Capital Management LLC now owns 719 shares of the biopharmaceutical company’s stock worth $404,000 after buying an additional 194 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.